BioVie Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BIVI Nasdaq 2830 bioviepharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioVie Inc.

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference - Nov 20th, 2024 1:00 pm
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded - Nov 4th, 2024 1:00 pm
BioVie Inc. Announces Closing of Registered Direct Offering - Oct 29th, 2024 8:05 pm
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Oct 28th, 2024 8:10 pm
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Oct 28th, 2024 7:13 pm
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement - Oct 24th, 2024 8:10 pm
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - Oct 23rd, 2024 7:24 pm
BioVie Announces Stock Offering and Private Placement - Oct 23rd, 2024 1:19 pm
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 - Oct 23rd, 2024 12:00 pm
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin - Oct 15th, 2024 12:00 pm
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Oct 11th, 2024 1:00 pm
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin - Oct 1st, 2024 12:00 pm
BioVie Inc. Announces Closing of Public Offering - Sep 25th, 2024 8:05 pm
BioVie Inc. Announces Pricing of Public Offering - Sep 24th, 2024 2:26 am
BioVie Inc. Announces Proposed Public Offering - Sep 23rd, 2024 8:05 pm
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID - Sep 16th, 2024 12:00 pm
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID - Sep 3rd, 2024 12:00 pm
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting - Aug 27th, 2024 12:45 pm
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting - Aug 13th, 2024 12:00 pm
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease - Aug 8th, 2024 10:00 am